The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 544-549

  Kinon, Bruce J ^a   Ascher Svanum, Haya ^a   Adams, David H ^a   Chen, Lei ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT RESPONSE; ADOLESCENT; HOSPITALIZATION; META ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 58149109328     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318185e74a     Document Type: Article

References (37)

1. Beasley CM Jr, Stauffer VL, Liu-Seifert H, et al. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol. 2007;27:252-258.
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
3. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28:199-206.
4. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121-1128.
5. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805-811.
6. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54:508-516.
7. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
8. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.
9. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
10. Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment ofschizophrenia in usual care. J Clin Psychiatry. 2006;67:453-460.
11. Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreni- form disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68: 1163-1171.
12. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
13. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17: 407-418.
14. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879-1887.
15. Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006;26:157-162.
16. Kinon BJ, Noordsy DL, Liu-Seifert H, et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol. 2006;26: 453-461.
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
18. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
19. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, Md: National Institute of Mental Health; 1976.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
21. Frances A, Pincus HA, First MB. The Global Assessment ofFunctioning Scale (GAF). Diagnostic and Statistical Manual of Mental Disorder IV. Washington, DC: American Psychiatric Association; 1994.
22. El Yajazi M, Battas O, Agoub M, et al. Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. Schizophr Res. 2002;56:121-127.
23. Lee KH, Harris AW, Loughland CM, et al. The five symptom dimensions and depression in schizophrenia. Psychopathology. 2003; 36:226-233.
24. Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull. 2008;34:286-291.
25. Ross DJ, Guggenheim FG. Compliance and the health belief model: a challenge for the liaison psychiatrist. Gen Hosp Psychiatry. 1983;5: 31-35.
26. Kinon BJ, Hill AL, Liu H, et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int JNeuropsychopharmacol. 2003;6:97-102.
27. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56.
28. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-508.
29. Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005; 162:939-946.
30. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228-1235.
31. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57:1543-1549.
32. Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160: 2063-2065.
33. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res [published online ahead of print April 17 2008]. 2008. Available at: http://www.sciencedirect.com/science? -ob=ArticleURL&-udi= B6TC2-4S9NGBG-1&-user=499562&- rdoc = 1 &-fmt=&-orig = search&-sort=d& view=c&-acct=C000024438&-version=1&- urlVersion=0&-userid=499562&md5= 291a5a7a4e2dbb175db2ac89e1edfbf1. Accessed May 12, 2008.
34. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull [published online ahead of print December 21 2007]. 2007. Available at: http://schizo- phreniabulletin.oxfordjournals.org/cgi/content/full/sbm134v1?maxtosh-ow= &HITS=10&hits=10&RESULTFORMAT=&fulltext=Nyhuis& searchid=1&FIRSTINDEX=0&resourcetype=HWCIT. Accessed May 2008.
35. Siris SG, Addington D, Azorin JM, et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res. 2001;47: 185-197.
36. Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165-171.
37. Peralta V, Cuesta MJ. The deficit syndrome of the psychotic illness. A clinical and nosological study. Eur Arch Psychiatry Clin Neurosci. 2004;254:165-171.